October Upside Ranks
Qualitative relative target-touch selections · Not calibrated probabilities
Dated prices · targets are price touches, not forecasts · exact ranks are editorial judgments.
Grade legend, dates & research limits
Completed editorial grades · assessed October 6. Business = demonstrated commercial traction. Catalyst = clarity and timing of the next important test, not success odds. Target path = how demanding this list’s target is. These grades use the same rubric for all selected names; they are not native financial-model grades or statistical probabilities.
A strong / direct · B supported but conditional · C speculative or major gaps · D exceptional leap / weak bridge. A strong catalyst can fail. A fivefold target can have a D path even in a top-ranked moonshot.
Exact grading benchmarks & evidence dates
Business
How far the business inflection is demonstrated today, not source completeness.
- A — Broad, realized commercial growth or earnings; not just a plan.
- B — Real but early, concentrated or mixed operating traction.
- C — Primarily clinical/development or capacity optionality; limited realized economics.
- D — Retained facts undermine the proposed business inflection.
Catalyst
Specificity, observability and timing of a thesis-changing test inside the original window, not its chance of success.
- A — A scheduled or explicitly windowed material readout, launch or commercial ramp; repeated hard operating tests may qualify.
- B — Concrete delivery, orders or earnings tests, but diffuse timing or less discrete thesis change.
- C — A real milestone with important acceptance/economics/timing gaps.
- D — No supported material in-window test.
Target path
Burden of reaching THIS tier target from the dated baseline; not an absolute odds estimate.
- A — Comparatively direct earnings/recognition bridge in retained evidence; still conditional.
- B — Recognizable bridge, but meaningful premium, execution or share-claim sensitivity.
- C — Speculative extension or binary rerating beyond established economics; small-base elasticity is not a forecast.
- D — Exceptional leap far beyond retained cases, with major scale/valuation/financing obstacles.
No bell curve, numeric weights, A+ grades, probability conversion or grade-based reranking. Same rubric for incumbents and additions; target-path grades vary by tier. A catalyst can fail. No synchronized chart grading because technical coverage is not comparable across all 19.
Assessment October 6 of retained evidence, not an October 6 source refresh. Baseline October 1; existing remaining touch window October 4, 2026 to exclusive October 1, 2027. Original source cutoff October 3; additions retrieved October 4; Bloom narrative retrieved October 5 UTC. Original publication dates remain attached to sources.
Original conservative research grades remain in each full story. Partial financial underwriting remains partial: completed qualitative grades do not certify current cash, target dilution, clinical efficacy or funded forecasts. No chart grade is invented from unmatched technical snapshots.
Targets use October 1, 2026 baseline quotes, which are not live prices. The price-touch window is October 4, 2026 to exclusive October 1, 2027, not the price at expiry. Exact ordinal differences are low-confidence editorial judgments; absolute likelihood may be low.
Original financial source cutoff: October 3, 2026, 07:14:12.687379 UTC. Biotech sources retrieved October 4 with original publication dates retained. Bloom’s power and policy narrative reviewed October 4 ET (sources retrieved October 5 UTC). Publication does not clear research or model limitations. No calibrated odds.
CERT · CERT
Research only — not selected in current October lists.
Oct1 baseline: USD 9.34. Historical daily quote retrieved Oct4.
Detailed research, financial evidence & sources
Business
Model-informed drug development software and services; recurring SaaS/license exposure, not an owned drug binary.
Financial quality
Q2 revenue $93.271m (+1%); software $48.8m (+4%). Consulting/services cyclical. H1 continuing OCF$15.584m less PPE$1.252m and capitalized software$13.223m leaves $1.109m, not EBITDA-quality cash. Exclude divestiture cash$69.435m from recurring FCF. H1 total loss$64.033m includes discontinued loss$46.127m; continuing loss$17.906m.
Claims and dilution
Gross term loan$294.028m vs carrying$291.839m, $2.189m issuance costs. $100m revolver commitment undrawn June30, subject to covenants, not opening cash. June26 2031 maturity; scheduled annual~$2.963m amortization. H1 buyback cash$57.389m, employee tax$3.339m, acquisition contingent cash$20.121m are separate uses. 4.132510m unvested RSUs gross contingent; 2.625006m June30 nonvested PSUs known; service, revenue/FCF/EBITDA performance and market conditions; current/target payout and options unresolved. $50m further buyback authorization not actual repurchase.
Guide / interpretation
2026 continuing revenue$367-382m, adjusted EBITDA margin29-31%, adjusted diluted EPS$0.31-0.36, diluted shares155-157m. Not GAAP EPS and not October-to-October guide.
Countercase
Low starting valuation could make modest growth and buybacks sufficient for+35%; Oct1 quote resolved; future earnings/claim uncertainty remains. Recurring software stability beats binary biotech risk but current 1% growth does not establish 2x/5x inflection.
Concrete catalysts — not efficacy promises
- Quarterly bookings/software growth and margin recovery, no owned clinical event required.
- Regulatory/medical writing divestiture closed May8; continuing comparisons restated.
Dated reported financial evidence
US GAAP unaudited consolidated; flows 2026-01-01 through2026-06-30 inclusive; stocks June30 unless dated share cover. Units: reported USD millions unless a share count, ratio or date is explicitly named. These are not October 4 bank balances.
- cash
- 184.138
- securities
- Unknown (null)
- liquid
- 184.138
- restricted
- Unknown (null)
- debt
- 294.028
- debt carrying
- 291.839
- debt and finance lease
- Unknown (null)
- op leases
- 10.106
- revenue
- 187.363
- operating income
- -6.46
- net income
- -64.033
- continuing net income
- -17.906
- ocf
- 15.584
- total ocf
- 21.732
- capex
- 1.252
- capitalized software
- 13.223
- sbc ocf
- 13.414
- sbc expense
- 13.414
- shares
- 152,538,780
- share date
- 2026-08-01
- weighted
- 156,046,326
- rsus
- 4,132,510
- options
- Unknown (null)
- unvested psus
- 2,625,006
Target burdens — static sensitivities, not forward fair value
Static reverse burden not forward fairvalue/funded hitcase; unknown actual current claims/cash not replaced by these dated balances.
1.35× baseline · USD 12.609
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 152.539
- datedLiquidityUSDm
- 184.138
- datedDebtUSDm
- 294.028
- requiredCommonEquityUSDm
- 1,923.362
- staticEVUSDm
- 2,033.252
2× baseline · USD 18.68
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 152.539
- datedLiquidityUSDm
- 184.138
- datedDebtUSDm
- 294.028
- requiredCommonEquityUSDm
- 2,849.424
- staticEVUSDm
- 2,959.314
5× baseline · USD 46.7
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 152.539
- datedLiquidityUSDm
- 184.138
- datedDebtUSDm
- 294.028
- requiredCommonEquityUSDm
- 7,123.561
- staticEVUSDm
- 7,233.451
Target-specific terminal shares: Unknown (null). Target-specific terminal cash: Unknown (null).
Discovery chart context
recovery · QQQ-relative discovery only, separate from AI100 runtime SPY scoring. Retained Oct1/Oct2 observations retrieved Oct4; no numerical rank against all incumbents.
- return20d
- 0.149
- return60d
- 0.376
- return120d
- 0.613
- distanceHigh
- -0.327
- range20d
- 0.3
- relative60d
- 0.349
Risks and unresolved inputs
- Oct4 actual liquid balances
- Target-dependent dilution and future issuance
- Market expectations baseline
- Exact forecast peak cash
- CERT-10Q
Published: 2026-08-04 · Retrieved: 2026-10-04T14:05:02.649558+00:00 - CERT-facts
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.650385+00:00 - CERT-release
Published: 2026-08-04 · Retrieved: 2026-10-04T14:04:38.294055+00:00 - CERT-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:04:38.147025+00:00